Brief: Keros Therapeutics Presents Study Results
09/06/2023 12:59
June 9 (Reuters) - Keros Therapeutics Inc KROS.O :
* KEROS THERAPEUTICS PRESENTS CLINICAL TRIAL AND PRECLINICAL
STUDY
RESULTS FROM ITS KER-050 PROGRAM AND PRECLINICAL DATA FROM ITS
ALK2 INHIBITOR PROGRAM AT THE 28TH ANNUAL CONGRESS OF THE
EUROPEAN HEMATOLOGY ASSOCIATION
Source text for Eikon: ID:nGNX82bfNQ
Further company coverage: KROS.O
(reuters.briefs@thomsonreuters.com)
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops